Spago Nanomedical Interim Report January-March, 2025

About this update from Spago Nanomedical Ab

[{"type":"text","content":"LUND, SE / ACCESS Newswire / May 7, 2025 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F)","length":87,"tagName":"p"},{"type":"text","content":"OCTOBER - DECEMBER IN BRIEF","length":27,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Net sales for the quarter amounted to KSEK 338 (KSEK 350)","length":57,"tagName":"p"}]},{"val":[{"type":"text","content":"The loss for the quarter amounted to KSEK -7,435 (KSEK -7,763)","length":62,"tagName":"p"}]},{"val":[{"type":"text","content":"Operating expenses for the quarter amounted to KSEK -8,964 (KSEK -9,497)","length":72,"tagName":"p"}]},{"val":[{"type":"text","content":"Earnings per share, before and after dilution, for the quarter amounted to SEK -0.02 (SEK -0.03)","length":96,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash and cash equivalents at the end of the quarter amounted to KSEK 26,578 (KSEK 32,250)","length":89,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":376,"olType":false},{"type":"text","content":"SIGNIFICANT EVENTS DURING THE QUARTER","length":37,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"A manuscript on product candidate pegfosimer manganese has been accepted for publication in the highly regarded peer reviewed scientific journal Investigative Radiology. The publication provides further scientific support for the SpagoPix development program.","length":259,"tagName":"p"}]},{"val":[{"type":"text","content":"The independent data monitoring committee, DMC, recommended a dose increase in the ongoing phase I/IIa study Tumorad-01 with 177 Lu-SN201. The recommendation was based on the analysis of data from two patient groups, consisting of six patients with five different cancer types. Both groups show a similar acceptable safety profile. A total of eight patients with seven different tumor types have now been dosed, of which one on the new higher dose and one on the lower dose.","length":474,"tagName":"p"}]},{"val":[{"type":"text","content":"For the 2025 Annual General Meeting, the nomination committee proposes the election of current board member Alan Raffensperger as the new chairman of the board and the election of oncologist Dr. Mikael von Euler as a new board member. To better reflect the stage that Spago Nanomedical is in, the nomination committee assesses that the company is in need of a chairma...

More updates from Spago Nanomedical Ab